AIA Group Ltd Has $9.87 Million Position in Quest Diagnostics Incorporated $DGX

AIA Group Ltd lessened its holdings in Quest Diagnostics Incorporated (NYSE:DGX) by 8.7% in the first quarter, HoldingsChannel reports. The fund owned 50,374 shares of the medical research company’s stock after selling 4,777 shares during the period. AIA Group Ltd’s holdings in Quest Diagnostics were worth $9,872,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Moneta Group Investment Advisors LLC boosted its holdings in Quest Diagnostics by 3.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 1,387 shares of the medical research company’s stock valued at $241,000 after purchasing an additional 50 shares during the period. HB Wealth Management LLC raised its position in shares of Quest Diagnostics by 0.5% in the fourth quarter. HB Wealth Management LLC now owns 11,292 shares of the medical research company’s stock valued at $1,960,000 after buying an additional 58 shares in the last quarter. Ossiam raised its position in shares of Quest Diagnostics by 6.1% in the third quarter. Ossiam now owns 1,059 shares of the medical research company’s stock valued at $202,000 after buying an additional 61 shares in the last quarter. Independent Advisor Alliance boosted its stake in shares of Quest Diagnostics by 1.6% in the fourth quarter. Independent Advisor Alliance now owns 4,298 shares of the medical research company’s stock valued at $746,000 after buying an additional 66 shares during the period. Finally, Fulton Bank N.A. boosted its stake in shares of Quest Diagnostics by 1.7% in the fourth quarter. Fulton Bank N.A. now owns 4,180 shares of the medical research company’s stock valued at $725,000 after buying an additional 68 shares during the period. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Quest Diagnostics Stock Performance

Shares of DGX stock opened at $210.87 on Friday. The business’s 50-day moving average price is $200.52 and its 200-day moving average price is $196.13. Quest Diagnostics Incorporated has a 12 month low of $165.30 and a 12 month high of $219.20. The firm has a market capitalization of $23.34 billion, a price-to-earnings ratio of 23.30, a PEG ratio of 2.51 and a beta of 0.58. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.67.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Tuesday, April 21st. The medical research company reported $2.50 EPS for the quarter, topping analysts’ consensus estimates of $2.37 by $0.13. Quest Diagnostics had a net margin of 9.07% and a return on equity of 15.60%. The company had revenue of $2.90 billion for the quarter, compared to analyst estimates of $2.83 billion. During the same quarter in the previous year, the business earned $1.94 earnings per share. Quest Diagnostics’s revenue was up 9.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. Equities research analysts forecast that Quest Diagnostics Incorporated will post 10.72 EPS for the current year.

Quest Diagnostics Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 22nd. Shareholders of record on Wednesday, July 8th will be issued a $0.86 dividend. This represents a $3.44 dividend on an annualized basis and a yield of 1.6%. The ex-dividend date is Wednesday, July 8th. Quest Diagnostics’s dividend payout ratio (DPR) is presently 38.01%.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on DGX shares. Wall Street Zen raised Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Evercore set a $225.00 price objective on shares of Quest Diagnostics in a research report on Tuesday, April 21st. Jefferies Financial Group reiterated a “buy” rating and set a $225.00 price objective on shares of Quest Diagnostics in a research note on Tuesday, April 21st. Weiss Ratings raised shares of Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday, July 9th. Finally, Truist Financial boosted their target price on shares of Quest Diagnostics from $220.00 to $225.00 and gave the company a “hold” rating in a research report on Wednesday, April 22nd. Seven investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $217.17.

Insiders Place Their Bets

In other news, CEO J. E. Davis sold 10,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $194.14, for a total value of $1,941,400.00. Following the completion of the sale, the chief executive officer directly owned 132,423 shares in the company, valued at $25,708,601.22. This trade represents a 7.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total value of $1,629,400.00. Following the transaction, the senior vice president directly owned 13,510 shares in the company, valued at $2,702,000. The trade was a 37.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.88% of the company’s stock.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.